Genentech Reports Positive Phase II Vismodegib Results
By Tom Wall
Tuesday, June 21, 2011
A pivotal Phase II study of oral medicine vismodegib (RG3616/GDC-0449) showed positive results in people with inoperable, advanced basal cell carcinoma (BCC), a rare form of skin cancer, reported Genentech Inc., of South San Francisco, a member of the Roche Group.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.